Solbec completes Phase I psoriasis trial
Wednesday, 09 February, 2005
Solbec Pharmaceuticals (ASX: SBP) has announced successful completion of its Phase I study of its devil's apple-derived drug Coramsine as a treatment for psoriasis.
Preliminary results from the trial, which incorporated two stages to look at the safety and tolerability in healthy individuals, plus a third stage to assess efficacy in ten patients with psoriasis, indicate that there were no treatment-related adverse events during the trial. The drug was administered in a cream formulation and in the efficacy stage of the trial, was compared to both placebo and to a standard treatment for psoriasis over a period of 56 days.
The company said efficacy results would be reported in the second quarter of this year, once the trial has been unblinded and data analysed.
Babies of stressed mothers likely to get their teeth earlier
Maternal stress during pregnancy can speed up the timing of teeth eruption, which may be an early...
Customised immune cells used to fight brain cancer
Researchers have developed CAR-T cells — ie, genetically modified immune cells manufactured...
Elevated blood protein levels predict mortality
Proteins that play key roles in the development of diseases such as cancer and inflammation may...
